SHANK Antibody [N23b/49 (Formerly sold as S23b-49)]
SHANK Antibody [N23b/49 (Formerly sold as S23b-49)] is a mouse monoclonal antibody directed against SHANK, offered by Assay Genie for research applications. Reported applications include WB, IHC, IP, ICC/IF and AM. Reported reactivity: Human, Mouse and Rat. Supplied as IgG1, purified by Protein G.
SHANK proteins are a family of postsynaptic scaffolding proteins that organize receptor and signaling complexes at excitatory synapses. They contain multiple protein interaction domains, including ankyrin repeats, SH3, PDZ, and SAM domains, enabling them to link neurotransmitter receptors to the actin cytoskeleton. SHANK proteins regulate synaptic strength, dendritic spine morphology, and receptor trafficking. Disruption of SHANK-mediated scaffolding impairs glutamate receptor localization and contributes to synaptic loss—a key feature of Alzheimer’s disease. SHANK family members also influence receptor tyrosine kinase signaling and are involved in neurodevelopmental processes. Their dysregulation has been associated with autism spectrum disorders, schizophrenia, and intellectual disability, making them central to both neurodevelopmental and neurodegenerative research. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.
Product Name:
SHANK Antibody [N23b/49 (Formerly sold as S23b-49)]
Cortactin binding protein 1, Cortactin SH3 domain-binding protein, Cortactin-binding protein 1, CortBP1, CTTNBP1, GKAP/SAPAP interacting protein, GKAP/SAPAP-interacting protein, KIAA1022, Proline rich synapse associated protein 1, Proline-rich synapse-associated protein 1, ProSAP1, SH3 and multiple ankyrin repeat domains protein 2, SHAN2_RAT, Shank2, SPANK-3
References:
1. Sheng M., and Kim E. (2000) Journal of Cell Science. 113: 1851-1856. 2. Kim J.H., et al. (2009) Exp Mol Med. 41(4): 236-242. 3. Gong Y., et al. (2009) Brain Res. 1292: 191-198.
